Ideate Ipilimumab Drug Evaluation Trademark Details

Ideate Ipilimumab Drug Evaluation was registered on Tuesday, September 1, 2015 and is currently owned by Bristol-Myers Squibb Company under the registration number 4802230 . This mark is alive with a status of Registered. The last case file activity for this mark occured 8 years ago on Tuesday, September 1, 2015, according to the United State Patent & Trademark Office
Word Mark Ideate Ipilimumab Drug Evaluation
Status Alive Registered 700 — Registered

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 86337421
Registration Number 4802230
Status Date Tuesday, September 1, 2015
Filing Date Tuesday, September 1, 2015
Registration Date Tuesday, September 1, 2015
Attorney Marilyn F. Kelly

Correspondent

MARILYN F. KELLY
PO BOX 4000
PRINCETON, NJ 08543-4000

Case File Statements

Disclaimer with Predetermined Text "Ipilimumab Drug Evaluation"
Goods & Services Providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Monday, July 21, 2014
First Use Anywhere Friday, May 31, 2013
First Use In Commerce Friday, May 31, 2013
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.